Price
No data yet.
Social Signal Score
Analyst Ratings
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.00
- Country
- ES
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
SABhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·17d ago·Neutral
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026
View source ↗ - Newsglobenewswire.com·24d ago·Negative
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026 Presentation will highlight Virtue SAB's fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. Virtue SAB's mechanism is designed to achieve sustained, transmural sirolimus tissue levels substantially exceeding those achieved by drug-eluting stents and drug-coated balloons.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its third quarter 2026 financial results will be issued on the morning of Thursday, November 5, 2026. Management will ho…
View source ↗ - Newsmarketbeat.com·30d ago·Neutral
SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform Executives from Healios and SAB Biotherapeutics NASDAQ: SABS outlined their approaches to developing scalable biologic therapies during a Chardan discussion focused on complex treatments designed for commercial manufacturing.
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12th, 2026, at 3:00pm ET in New York City.
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the upcoming Chardan 10th Annual Healthcare Conference: Date: October 20, 2026Time: 11:15 - 11:30 a.m. ETFormat: Fi…
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes
View source ↗ - Newsglobenewswire.com·52d ago·Negative
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) being held October 9-11, 2026 in Philadelphia, …
View source ↗ - Newsglobenewswire.com·61d ago·Negative
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) being held Sep…
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
SAB BIO to Participate in Upcoming Investor Conferences MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in upcoming investor conferences in September:
View source ↗
Congress trades
No disclosed congressional trades in SAB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
